219 related articles for article (PubMed ID: 10416001)
1. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R
Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001
[TBL] [Abstract][Full Text] [Related]
2. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH
Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
O'Meara A; Halter J; Heim D; Gerull S; Bucher C; Passweg J; Buser A; Stern M
Biol Blood Marrow Transplant; 2013 Jan; 19(1):82-6. PubMed ID: 22897965
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
6. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
8. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
9. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Au WY; Lie AK; Siu LL; Chan EC; Ooi GC; Leung AY; Liang R; Kwong YL
Ann Hematol; 2003 Sep; 82(9):548-51. PubMed ID: 14504811
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
[TBL] [Abstract][Full Text] [Related]
14. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
15. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
16. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
17. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J
Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
Chamoun K; Milton DR; Ledesma C; Young KH; Jabbour EJ; Alatrash G; Anderlini P; Bashir Q; Ciurea SO; Marin D; Molldrem JJ; Olson AL; Oran B; Popat UR; Rondon G; Champlin RE; Gulbis AM; Khouri IF
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1347-1354. PubMed ID: 30826465
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
[TBL] [Abstract][Full Text] [Related]
20. BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
Fair C; Shanley R; Rogosheske J; Lazaryan A; McClune B; Brunstein CG; Bachanova V
Bone Marrow Transplant; 2017 Mar; 52(3):491-493. PubMed ID: 28067889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
